[go: up one dir, main page]

WO2006110585A3 - Cancer-related genes (prlr) - Google Patents

Cancer-related genes (prlr) Download PDF

Info

Publication number
WO2006110585A3
WO2006110585A3 PCT/US2006/013160 US2006013160W WO2006110585A3 WO 2006110585 A3 WO2006110585 A3 WO 2006110585A3 US 2006013160 W US2006013160 W US 2006013160W WO 2006110585 A3 WO2006110585 A3 WO 2006110585A3
Authority
WO
WIPO (PCT)
Prior art keywords
prlr
cancer
related genes
expression
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/013160
Other languages
French (fr)
Other versions
WO2006110585A2 (en
Inventor
Abdallah Fanidi
Robert Booher
Christin Tse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Sagres Discovery Inc
Original Assignee
Sagres Discovery Inc
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sagres Discovery Inc, Chiron Corp filed Critical Sagres Discovery Inc
Priority to US11/910,837 priority Critical patent/US20090220495A1/en
Priority to EP06749567A priority patent/EP1871911A2/en
Priority to JP2008505603A priority patent/JP2008535494A/en
Publication of WO2006110585A2 publication Critical patent/WO2006110585A2/en
Publication of WO2006110585A3 publication Critical patent/WO2006110585A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

This invention is in the field of cancer-associated genes. Specifically it relates to methods for detecting cancer or the likelihood of developing cancer based on the presence or absence of expression of a PRLR gene or protein. The invention also provides methods and molecules for upregulating or downregulating PRLR gene expression and PRLR protein activity.
PCT/US2006/013160 2005-04-07 2006-04-07 Cancer-related genes (prlr) Ceased WO2006110585A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US11/910,837 US20090220495A1 (en) 2005-04-07 2006-04-07 Cancer Related Genes (PRLR)
EP06749567A EP1871911A2 (en) 2005-04-07 2006-04-07 Cancer-related genes (prlr)
JP2008505603A JP2008535494A (en) 2005-04-07 2006-04-07 Cancer-related gene (PRLR)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66986105P 2005-04-07 2005-04-07
US60/669,861 2005-04-07

Publications (2)

Publication Number Publication Date
WO2006110585A2 WO2006110585A2 (en) 2006-10-19
WO2006110585A3 true WO2006110585A3 (en) 2006-12-21

Family

ID=36809257

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2006/013160 Ceased WO2006110585A2 (en) 2005-04-07 2006-04-07 Cancer-related genes (prlr)
PCT/US2006/013153 Ceased WO2006110581A2 (en) 2005-04-07 2006-04-07 Cancer-related genes

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2006/013153 Ceased WO2006110581A2 (en) 2005-04-07 2006-04-07 Cancer-related genes

Country Status (6)

Country Link
US (1) US20090220495A1 (en)
EP (3) EP2083088A3 (en)
JP (2) JP2008535494A (en)
AU (1) AU2006235258A1 (en)
CA (1) CA2604844A1 (en)
WO (2) WO2006110585A2 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8680069B2 (en) 2011-12-16 2014-03-25 Moderna Therapeutics, Inc. Modified polynucleotides for the production of G-CSF
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9005614B2 (en) 2006-08-18 2015-04-14 Novartis Ag PRLR-specific antibody and uses thereof
US9107886B2 (en) 2012-04-02 2015-08-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding basic helix-loop-helix family member E41
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9334328B2 (en) 2010-10-01 2016-05-10 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005235811B2 (en) 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
CN103554259B (en) 2005-10-12 2016-05-18 莫佛塞斯公司 Specificity is for generation and the qualification of the derivative treatment of the complete people HuCAL GOLD-antibody of people CD38
EP2412820A1 (en) 2006-01-11 2012-02-01 Genomic Health, Inc. Gene expression markers for colorectal cancer prognosis
WO2007134210A2 (en) * 2006-05-12 2007-11-22 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
EP2392673A1 (en) * 2006-06-02 2011-12-07 GlaxoSmithKline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy based on the differential expression of the FOXP3 gene
WO2007145840A2 (en) 2006-06-13 2007-12-21 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
JP5618544B2 (en) 2007-01-24 2014-11-05 オンコメッドファーマシューティカルズ インコーポレイテッド Compositions and methods for diagnosis and treatment of cancer
AU2008230880B2 (en) * 2007-03-23 2014-04-24 The Translational Genomics Research Institute Method of diagnosing, classifying and treating endometrial cancer and precancer
WO2008117067A2 (en) 2007-03-27 2008-10-02 Carl Arne Krister Borrebaeck Protein signature/markers for the detection of adenocarcinoma
EP2728018B1 (en) * 2007-06-01 2016-11-23 The Regents of The University of California Multigene prognostic assay for lung cancer
CA2691378A1 (en) 2007-07-02 2009-01-08 Oncomed Pharmaceuticals, Inc. Antibody against human r-spondin (rspo) and use thereof for inhibition of beta-catenin signaling and treatment of cancer
EP2728017B1 (en) * 2007-11-19 2016-08-24 Celera Corporation Lung cancer markers and uses thereof
WO2009117018A1 (en) * 2008-03-20 2009-09-24 Transmolecular, Inc. Inhibition of angiogenesis
BRPI0912683A2 (en) 2008-05-15 2016-01-26 Transmolecular Inc treatment of metastatic tumors
WO2010002862A2 (en) 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
NZ590127A (en) 2008-07-08 2012-11-30 Oncomed Pharm Inc Notch1 receptor binding agents and methods of use thereof
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
EP2373338B1 (en) * 2008-12-03 2017-02-15 The Johns Hopkins University Annexina2 as immunological target
CA2760333A1 (en) 2009-05-01 2010-11-04 Genomic Health Inc. Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy
AU2011205316B2 (en) 2010-01-13 2015-05-28 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
AU2011213678B2 (en) 2010-02-04 2015-01-29 Eisai Inc. Chlorotoxin polypeptides and conjugates and uses thereof
ES2601182T3 (en) 2010-05-11 2017-02-14 Fred Hutchinson Cancer Research Center Chlorotoxin variants, conjugates and methods for their use
GB201103726D0 (en) 2011-03-04 2011-04-20 Immunovia Ab Method, array and use thereof
WO2012136519A1 (en) 2011-04-06 2012-10-11 Bayer Pharma Aktiengesellschaft Use of neutralizing prolactin receptor antibodies for the treatment and prevention of antiestrogen-resistant breast cancer
EP2530089A1 (en) 2011-06-03 2012-12-05 Bayer Pharma Aktiengesellschaft Neutralising prolactin receptor antibody Mat3 and its therapeutical use
MX349198B (en) 2011-07-15 2017-07-18 Oncomed Pharmaceuticals Inc * AGENTS THAT JOIN THE R-SPONDIN PROTEINS (RSPO) AND USES OF THE SAME.
WO2013044164A1 (en) * 2011-09-21 2013-03-28 The Regents Of The University Of California Methods to treat and/or prevent relapse in notch1-driven malignancies
KR102148303B1 (en) * 2012-02-11 2020-08-26 제넨테크, 인크. R-spondin translocations and methods using the same
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013166153A2 (en) * 2012-05-01 2013-11-07 Brentnall Teri Methods and compositions for cancer diagnosis
JP6335118B2 (en) * 2012-05-11 2018-05-30 国立研究開発法人国立がん研究センター Prognosis prediction method for renal cell carcinoma
KR20150036603A (en) 2012-07-13 2015-04-07 온코메드 파마슈티칼스, 인크. Rspo3 binding agents and uses thereof
SG11201504600UA (en) 2012-12-10 2015-07-30 Hutchinson Fred Cancer Res Methods for screening
TWI582239B (en) * 2013-03-11 2017-05-11 諾華公司 Markers associated with WNT inhibitors
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
JP2015008686A (en) * 2013-06-28 2015-01-19 三菱レイヨン株式会社 Method for evaluating the state of cells derived from liver cells or their precursor cells, and probes or probe sets and microarrays used in the method
US9567641B2 (en) 2013-07-03 2017-02-14 Samsung Electronics Co., Ltd. Combination therapy for the treatment of cancer using an anti-C-met antibody
WO2015035415A1 (en) 2013-09-09 2015-03-12 Nantomics, Llc Method of detecting suceptibility to breast cancer through mutations in the fgfr3 and tp53 genes
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
CN105980401A (en) 2013-10-03 2016-09-28 现代治疗公司 Polynucleotides encoding low density lipoprotein receptor
GB201319878D0 (en) * 2013-11-11 2013-12-25 Immunovia Ab Method, Array and use thereof
CA2935903A1 (en) 2014-01-09 2015-07-16 Hadasit Medical Research Services And Development Ltd. Improved cell compositions and methods for cancer therapy
US9994912B2 (en) 2014-07-03 2018-06-12 Abbott Molecular Inc. Materials and methods for assessing progression of prostate cancer
CA2961374A1 (en) 2014-09-16 2016-03-24 Oncomed Pharmaceuticals, Inc. Treatment of fibrotic diseases
HK1256498A1 (en) 2015-07-30 2019-09-27 Modernatx, Inc. Concatemeric peptide epitope rnas
US12048732B2 (en) 2016-04-15 2024-07-30 Blaze Bioscience, Inc. Methods of treating breast cancer
EP3665307B1 (en) 2017-08-10 2022-09-28 The Institute of Cancer Research: Royal Cancer Hospital Materials and methods for stratifying and treating cancers
WO2019112489A1 (en) * 2017-12-05 2019-06-13 Limited Liability Company "Gero" Methods and agents for treatment of aging and aging related conditions and diseases
EP3752252A4 (en) 2018-02-12 2021-11-17 Hadasit Medical Research Services and Development Ltd. MODULATION OF SLAMF6 SPLICE VARIANTS FOR CANCER THERAPY
KR101890392B1 (en) * 2018-05-28 2018-08-21 의료법인 성광의료재단 A composition, and marker for diagnosing ovarian cancer comprising WNT3A
KR20200115883A (en) * 2019-03-28 2020-10-08 황인후 Composition for prevention, improvement or treatment of pancreatic cancer comprising tetraspanin-2 inhibitor
KR102169901B1 (en) * 2019-05-17 2020-10-26 연세대학교 산학협력단 Methods for providing information about responses to cancer immunotherapy using dna methylation and kits using the same
US20220326243A1 (en) * 2019-05-21 2022-10-13 Acurasysbio Co., Ltd. Composition for cancer diagnosis
IL267614A (en) * 2019-06-24 2019-09-26 Lotem Michal Nucleic acid agents modulating slamf6 isoforms
JP2023512151A (en) * 2019-12-25 2023-03-24 シャンハイ・エックスビーエイチ・バイオテクノロジー・カンパニー・リミテッド Compositions and methods for treating autoimmune diseases and cancer by targeting IGSF8
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
CN114487418A (en) 2022-02-17 2022-05-13 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） Application of TGFb RIII protein as gastric cancer serum biomarker

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002050098A2 (en) * 2000-12-18 2002-06-27 Genaissance Pharmaceuticals, Inc. Haplotypes of the prlr gene
WO2003004989A2 (en) * 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003008583A2 (en) * 2001-03-02 2003-01-30 Sagres Discovery Novel compositions and methods for cancer
US20030064383A1 (en) * 2000-12-22 2003-04-03 Morris David W. Novel compositions and methods in cancer associated with altered expression of PRLR

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US5430136A (en) 1984-10-16 1995-07-04 Chiron Corporation Oligonucleotides having selectably cleavable and/or abasic sites
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
DE3675588D1 (en) 1985-06-19 1990-12-20 Ajinomoto Kk HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE).
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US4956453A (en) 1985-12-06 1990-09-11 Cetus Corporation Anti-human ovarian cancer immunotoxins and methods of use thereof
US4868105A (en) 1985-12-11 1989-09-19 Chiron Corporation Solution phase nucleic acid sandwich assay
JPS63502716A (en) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー How to enhance glycoprotein stability
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5124246A (en) 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5359100A (en) 1987-10-15 1994-10-25 Chiron Corporation Bifunctional blocked phosphoramidites useful in making nucleic acid mutimers
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
CA2049028A1 (en) 1989-03-07 1990-09-08 Genentech, Inc. Covalent conjugates of lipid and oligonucleotide
WO1990011092A1 (en) 1989-03-21 1990-10-04 Vical, Inc. Expression of exogenous polynucleotide sequences in a vertebrate
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
EP0845537A1 (en) 1989-08-18 1998-06-03 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
WO1991004753A1 (en) 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
ES2284161T3 (en) 1990-01-12 2007-11-01 Amgen Fremont Inc. GENERATION OF XENOGENIC ANTIBODIES.
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
WO1992002526A1 (en) 1990-07-27 1992-02-20 Chiron Corporation Large comb-type branched polynucleotides
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69133476T2 (en) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgenic mice capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JP3337214B2 (en) 1990-12-20 2002-10-21 アーチ・ディベロップメント・コーポレーション Regulation of gene expression by ionizing radiation
DE69233482T2 (en) 1991-05-17 2006-01-12 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5419966A (en) 1991-06-10 1995-05-30 Microprobe Corporation Solid support for synthesis of 3'-tailed oligonucleotides
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
CA2115742A1 (en) 1991-08-20 1993-03-04 Ronald G. Crystal Adenovirus mediated transfer of genes to the gastrointestinal tract
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
JP4157160B2 (en) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド Methods for the preparation of modified antibody variable regions
CA2128616A1 (en) 1992-01-23 1993-08-05 Gary H. Rhodes Ex vivo gene transfer
FR2688514A1 (en) 1992-03-16 1993-09-17 Centre Nat Rech Scient Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
CA2118513A1 (en) 1992-04-24 1993-11-11 David A. Zarling In vivo homologous sequence targeting in eukaryotic cells
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS FOR TARGETING SPECIFIC TISSUES.
WO1993025698A1 (en) 1992-06-10 1993-12-23 The United States Government As Represented By The Vector particles resistant to inactivation by human serum
JPH07509137A (en) 1992-07-24 1995-10-12 セル　ジェネシス，インク． Production of xenoantibodies
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
PL174721B1 (en) 1992-11-13 1998-09-30 Idec Pharma Corp Monoclonal antibody anty-cd2
CA2592997A1 (en) 1992-12-03 1994-06-09 Genzyme Corporation Pseudo-adenovirus vectors
US5759573A (en) 1993-04-22 1998-06-02 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
WO1995000655A1 (en) 1993-06-24 1995-01-05 Mc Master University Adenovirus vectors for gene therapy
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
ES2328424T3 (en) 1993-09-15 2009-11-12 Novartis Vaccines And Diagnostics, Inc. RECOMBINANT ALFAVIRUS VECTORS.
WO1995011984A2 (en) 1993-10-25 1995-05-04 Canji, Inc. Recombinant adenoviral vector and methods of use
WO1995013796A1 (en) 1993-11-16 1995-05-26 Depotech Corporation Vesicles with controlled release of actives
US5681697A (en) 1993-12-08 1997-10-28 Chiron Corporation Solution phase nucleic acid sandwich assays having reduced background noise and kits therefor
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
ATE381624T1 (en) 1994-05-09 2008-01-15 Oxford Biomedica Ltd RETROVIRAL VECTORS WITH REDUCED RECOMBINATION RATE
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5580731A (en) 1994-08-25 1996-12-03 Chiron Corporation N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5681702A (en) 1994-08-30 1997-10-28 Chiron Corporation Reduction of nonspecific hybridization by using novel base-pairing schemes
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
ATE390933T1 (en) 1995-04-27 2008-04-15 Amgen Fremont Inc HUMAN ANTIBODIES AGAINST IL-8 DERIVED FROM IMMUNIZED XENOMICES
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
EP0877752B1 (en) 1996-01-23 2003-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and rna molecules
ATE424463T1 (en) 1996-05-06 2009-03-15 Oxford Biomedica Ltd RECOMBINATION-INCAPABLE RETROVIRAL VECTORS
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
DK1500329T3 (en) 1996-12-03 2012-07-09 Amgen Fremont Inc Human antibodies that specifically bind TNF-alpha
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
DK1071700T3 (en) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glycosylation modification of antibodies to enhance antibody-dependent cellular cytotoxicity
DE19956568A1 (en) 1999-01-30 2000-08-17 Roland Kreutzer Method and medicament for inhibiting the expression of a given gene
ES2569919T3 (en) 1999-04-09 2016-05-13 Kyowa Hakko Kirin Co., Ltd. Procedure to control the activity of an immunofunctional molecule
US6475220B1 (en) 1999-10-15 2002-11-05 Whiteside Biomechanics, Inc. Spinal cable system
JP2003516124A (en) 1999-10-15 2003-05-13 ユニバーシティー オブ マサチューセッツ RNA interference pathway genes as a means of targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US6406840B1 (en) 1999-12-17 2002-06-18 Biomosaic Systems, Inc. Cell arrays and the uses thereof
DE10019058A1 (en) * 2000-04-06 2001-12-20 Epigenomics Ag Designing primers and probes for analyzing diseases associated with cytosine methylation state e.g. arthritis, cancer, aging, arteriosclerosis comprising fragments of chemically modified genes associated with cell cycle
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7713526B2 (en) * 2001-05-01 2010-05-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7074175B2 (en) 2001-07-25 2006-07-11 Erik Schroeder Handy Thermotherapy via targeted delivery of nanoscale magnetic particles
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
JP2005532036A (en) * 2002-01-09 2005-10-27 理化学研究所 Cancer profile
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
ATE500326T1 (en) * 2002-06-06 2011-03-15 Oncotherapy Science Inc GENES AND PROTEINS RELATED TO HUMAN COLON CANCER
WO2004016317A1 (en) * 2002-08-14 2004-02-26 Erasmus University Medical Center Rotterdam Use of murine genomic regions identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer
SI1651162T1 (en) 2003-05-20 2016-02-29 Immunogen, Inc. Improved cytotoxic agents comprising new maytansinoids
WO2004105573A2 (en) * 2003-05-21 2004-12-09 The Wistar Institute Of Anatomy And Biology Method of diagnosis of cancer based on gene expression profiles in cells
CA2527321A1 (en) * 2003-05-30 2004-12-23 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
EP2003196A3 (en) * 2003-06-09 2009-01-07 The Regents of the University of Michigan Compositions and methods for treating and diagnosing cancer
JP2006526998A (en) * 2003-06-12 2006-11-30 コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジー Gastric cancer and metastatic gastric cancer diagnostic kit
CA2529819A1 (en) 2003-06-30 2004-09-23 Domantis Limited Pegylated single domain antibodies
JP2005073548A (en) * 2003-08-29 2005-03-24 National Cancer Center-Japan Use of HNF-1β for the examination, treatment and screening of therapeutic agents for ovarian clear cell adenocarcinoma
US20070054849A1 (en) * 2003-09-24 2007-03-08 Oncotherapy Science, Inc. Method for diagnosing hepatocellular carcinomas
US20050249723A1 (en) 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
KR101549245B1 (en) * 2004-09-21 2015-09-01 로드아일랜드 하스피털, 에이 라이프스팬 파트너 Wnt proteins and detection and treatment of cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002050098A2 (en) * 2000-12-18 2002-06-27 Genaissance Pharmaceuticals, Inc. Haplotypes of the prlr gene
US20030064383A1 (en) * 2000-12-22 2003-04-03 Morris David W. Novel compositions and methods in cancer associated with altered expression of PRLR
WO2003008583A2 (en) * 2001-03-02 2003-01-30 Sagres Discovery Novel compositions and methods for cancer
WO2003004989A2 (en) * 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 20 January 2002 (2002-01-20), GUAN YANXING ET AL: "Relationship between prolactin receptor and prognostic factors in breast cancer", XP002398952, Database accession no. PREV200200259368 *
GAGNERAULT M C ET AL: "Expression of prolactin receptors in murine lymphoid cells in normal and autoimmune situations.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 JUN 1993, vol. 150, no. 12, 15 June 1993 (1993-06-15), pages 5673 - 5681, XP002396074, ISSN: 0022-1767 *
GARCÍA-CABALLERO T ET AL: "Increased expression of growth hormone and prolactin receptors in hepatocellular carcinomas.", ENDOCRINE. JUN 2000, vol. 12, no. 3, June 2000 (2000-06-01), pages 265 - 271, XP008068085, ISSN: 0969-711X *
MENG JIANPING ET AL: "Human prolactin receptor variants in breast cancer: low ratio of short forms to the long-form human prolactin receptor associated with mammary carcinoma.", CANCER RESEARCH. 15 AUG 2004, vol. 64, no. 16, 15 August 2004 (2004-08-15), pages 5677 - 5682, XP002396070, ISSN: 0008-5472 *
PEIRCE S K ET AL: "Quantification of prolactin receptor mRNA in multiple human tissues and cancer cell lines by real time RT-PCR", JOURNAL OF ENDOCRINOLOGY, BRISTOL, GB, vol. 171, no. 1, October 2001 (2001-10-01), pages R1 - R4, XP002361681, ISSN: 0022-0795 *
See also references of EP1871911A2 *
TOURAINE P ET AL: "Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues.", THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM. FEB 1998, vol. 83, no. 2, February 1998 (1998-02-01), pages 667 - 674, XP002396071, ISSN: 0021-972X *
ZHONGGUO ZHONGLIU LINCHUANG, vol. 29, no. 1, 20 January 2002 (2002-01-20), pages 5 - 8, 19, ISSN: 1000-8179 *

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9005614B2 (en) 2006-08-18 2015-04-14 Novartis Ag PRLR-specific antibody and uses thereof
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9447164B2 (en) 2010-08-06 2016-09-20 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9334328B2 (en) 2010-10-01 2016-05-10 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9533047B2 (en) 2011-03-31 2017-01-03 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US8754062B2 (en) 2011-12-16 2014-06-17 Moderna Therapeutics, Inc. DLIN-KC2-DMA lipid nanoparticle delivery of modified polynucleotides
US9186372B2 (en) 2011-12-16 2015-11-17 Moderna Therapeutics, Inc. Split dose administration
US9295689B2 (en) 2011-12-16 2016-03-29 Moderna Therapeutics, Inc. Formulation and delivery of PLGA microspheres
US9271996B2 (en) 2011-12-16 2016-03-01 Moderna Therapeutics, Inc. Formulation and delivery of PLGA microspheres
US8680069B2 (en) 2011-12-16 2014-03-25 Moderna Therapeutics, Inc. Modified polynucleotides for the production of G-CSF
US9221891B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. In vivo production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9216205B2 (en) 2012-04-02 2015-12-22 Moderna Therapeutics, Inc. Modified polynucleotides encoding granulysin
US9149506B2 (en) 2012-04-02 2015-10-06 Moderna Therapeutics, Inc. Modified polynucleotides encoding septin-4
US9220792B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. Modified polynucleotides encoding aquaporin-5
US9220755B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders
US9233141B2 (en) 2012-04-02 2016-01-12 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9114113B2 (en) 2012-04-02 2015-08-25 Moderna Therapeutics, Inc. Modified polynucleotides encoding citeD4
US9192651B2 (en) 2012-04-02 2015-11-24 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9107886B2 (en) 2012-04-02 2015-08-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding basic helix-loop-helix family member E41
US9301993B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides encoding apoptosis inducing factor 1
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9095552B2 (en) 2012-04-02 2015-08-04 Moderna Therapeutics, Inc. Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1
US9089604B2 (en) 2012-04-02 2015-07-28 Moderna Therapeutics, Inc. Modified polynucleotides for treating galactosylceramidase protein deficiency
US9061059B2 (en) 2012-04-02 2015-06-23 Moderna Therapeutics, Inc. Modified polynucleotides for treating protein deficiency
US9050297B2 (en) 2012-04-02 2015-06-09 Moderna Therapeutics, Inc. Modified polynucleotides encoding aryl hydrocarbon receptor nuclear translocator
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9675668B2 (en) 2012-04-02 2017-06-13 Moderna Therapeutics, Inc. Modified polynucleotides encoding hepatitis A virus cellular receptor 2
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA

Also Published As

Publication number Publication date
US20090220495A1 (en) 2009-09-03
WO2006110581A3 (en) 2007-07-12
CA2604844A1 (en) 2006-10-19
WO2006110585A2 (en) 2006-10-19
JP2008535494A (en) 2008-09-04
WO2006110581A2 (en) 2006-10-19
EP2083088A2 (en) 2009-07-29
AU2006235258A1 (en) 2006-10-19
JP2008535853A (en) 2008-09-04
EP1871911A2 (en) 2008-01-02
EP2083088A3 (en) 2009-10-14
EP1910557A2 (en) 2008-04-16

Similar Documents

Publication Publication Date Title
WO2006110585A3 (en) Cancer-related genes (prlr)
WO2006110599A3 (en) Cacna1e in cancer diagnosis, detection and treatment
Kim et al. Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin
WO2007137187A3 (en) System and method for determining individualized medical intervention for a disease state
EP1750771A4 (en) PANCREATIC ILOT MICRO-RNA AND METHODS OF INHIBITING THE SAME
WO2005039382A3 (en) Prediction of likelihood of cancer recurrence
WO2007067500A3 (en) Predictors of patient response to treatment with egfr inhibitors
EP1985715A3 (en) ESR1 and cervical cancer
WO2008061213A3 (en) Genetic variations associated with tumors
WO2004071572A3 (en) Gene expression markers for response to egfr inhibitor drugs
WO2006110594A3 (en) Sema4d in cancer diagnosis, detection and treatment
WO2008073177A3 (en) Expression profiles associated with irinotecan treatment
ATE514090T1 (en) USE OF THE PROTEIN SATB2 AS A MARKER TO DIFFERENTIATE COLORECTAL CARCINOMA FROM OTHER CANCER DISEASES
WO2005034732A3 (en) Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
WO2006028655A3 (en) Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2006037462A3 (en) Cancer markers
WO2006134154A3 (en) Enpp1 (pc-1) gene haplotype associated with the risk of obesity and type 2 diabetes and their applications
WO2007087263A3 (en) Human zip1, zinc and citrate for prostate cancer screening
WO2008054595A3 (en) Drug controlled molecular tags
WO2006110587A3 (en) Ddr2 in cancer diagnosis, detection and treatment
WO2008108873A3 (en) Molecular biosensors for detecting macromolecules and other analytes
WO2008070325A3 (en) Genetic variations associated with tumors
WO2006110583A3 (en) Adam10 in cancer diagnosis, detection and treatment
WO2006110466A3 (en) CANCER-RELATED GENES (PTPϵ)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2008505603

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006749567

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 11910837

Country of ref document: US